Hologic, Inc. (HOLX) Receives Average Rating of “Buy” from Analysts

Hologic, Inc. (NASDAQ:HOLX) has received an average recommendation of “Buy” from the sixteen research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $48.36.

A number of equities research analysts have weighed in on the stock. Needham & Company LLC reissued a “buy” rating and issued a $50.00 price target (up from $48.00) on shares of Hologic in a report on Tuesday, January 9th. Deutsche Bank downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $49.00 price target for the company. in a report on Friday, January 19th. BidaskClub downgraded shares of Hologic from a “hold” rating to a “sell” rating in a report on Saturday, January 13th. Cowen raised shares of Hologic to a “buy” rating and set a $52.00 price target for the company in a report on Wednesday, December 20th. Finally, Bank of America upgraded Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price objective on the stock in a report on Thursday, January 4th.

Shares of Hologic (NASDAQ HOLX) opened at $37.75 on Friday. Hologic has a 1-year low of $35.33 and a 1-year high of $46.80. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.79 and a quick ratio of 0.61. The firm has a market cap of $10,729.33, a PE ratio of 9.96, a price-to-earnings-growth ratio of 1.81 and a beta of 0.77.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.05. Hologic had a net margin of 34.53% and a return on equity of 20.75%. The company had revenue of $791.10 million during the quarter, compared to the consensus estimate of $785.80 million. During the same period in the prior year, the company earned $0.52 EPS. Hologic’s revenue was up 7.7% on a year-over-year basis. equities research analysts anticipate that Hologic will post 2.18 earnings per share for the current fiscal year.

In other news, Director Elaine Ullian sold 9,282 shares of the company’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $40.50, for a total value of $375,921.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Karleen Marie Oberton sold 1,023 shares of the company’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $39.84, for a total value of $40,756.32. The disclosure for this sale can be found here. 0.79% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of HOLX. Grove Bank & Trust increased its holdings in shares of Hologic by 115.8% in the 3rd quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock valued at $105,000 after purchasing an additional 1,535 shares during the period. Hall Laurie J Trustee increased its holdings in shares of Hologic by 10.2% in the 2nd quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock valued at $110,000 after purchasing an additional 225 shares during the period. MPS Loria Financial Planners LLC acquired a new position in shares of Hologic in the 2nd quarter valued at about $191,000. NuWave Investment Management LLC acquired a new position in shares of Hologic in the 4th quarter valued at about $199,000. Finally, National Asset Management Inc. bought a new stake in shares of Hologic in the 2nd quarter valued at approximately $203,000. Institutional investors own 92.77% of the company’s stock.

WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/02/10/hologic-inc-holx-receives-average-rating-of-buy-from-analysts.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply